Latest Breaking News On - Diakonos oncology - Page 2 : comparemela.com

Diakonos Oncology s dendritic cell vaccine shows promise despite development hurdles

Cellipoint Bioservices signed an agreement with Diakonos Oncology in October 2023 for the development and manufacturing of DOC1021, an autologous dendritic cell (DC) vaccine.

United kingdomJasminemay barcelonDendreon provengeBiotherapeutic dcvaxHealthcare products regulatory agencyDiakonos oncologyFast track designationMarketing authorization applicationAivita biomedicalImmunomic therapeuticBio developmentsMarkets amp regulationsEmerging marketsClinical trials

Diakonos Oncology Awarded FDA Fast Track Designation for Innovative Dendritic Cell Vaccine for Glioblastoma

Diakonos Oncology Awarded FDA Fast Track Designation for Innovative Dendritic Cell Vaccine for Glioblastoma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUniversity of texasTexas medical centerUniversity of arizonaJoseph georgesWilliam deckerMike wicksDrug administrationDiakonos oncology corpUniversity of arizona college medicineUniversity of texas health science centerDiakonos oncology corporationOncology corporationFast trackChief executive officerAssociate professor

DOC1021 Gains FDA Fast Track Designation in Glioblastoma Multiforme

A fast track designation has been granted to DOC1021 by the FDA for the treatment of patients with glioblastoma multiforme.

New jerseyUnited statesUniversity of arizonaUniversity of texasTexas medical centerBaylor college of medicineJoseph georgesMike wicksWilliam deckerDiakonos oncology corporationUniversity of arizona college medicineUniversity of texas health science centerDiakonos oncologyArizona collegeBaylor collegeCancer center

Cellipont Bioservices and Diakonos Oncology Corporation Collaborate to Develop Groundbreaking Therapy for Glioblastoma

/PRNewswire/ Cellipont Bioservices, a leading CDMO in cell therapy development and manufacturing and Diakonos Oncology, announced today that they have.

United statesPrnewswire cellipont bioservicesCellipont bioservicesMike wicksOffice of diakonosDiakonos oncologyProcess developmentFast trackDarren headChief executive officeHealth care amp hospitalsMedical pharmaceuticalsFda approvalClinical trials amp medical discoveries